Eledon Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2023, Eledon was a clinical-stage biotechnology company developing tegoprubart, an anti-CD40L antibody, primarily for organ transplantation and also for ALS. The company had no approved products and had not generated product revenue. Its unaudited results are not necessarily indicative of future periods.
Financial results and liquidity
| Metric (USD millions, except per-share data) | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $8.113 | $6.635 |
| General and administrative expense | $2.997 | $3.224 |
| Total operating expenses / operating loss | $11.110 | $9.859 |
| Other income (expense), net | $0.338 | $(0.005) |
| Net loss | $(10.772) | $(9.864) |
| Basic and diluted loss per share | $(0.75) | $(0.69) |
| Net cash used in operating activities | $(9.924) | $(8.156) |
At March 31, 2023, cash and cash equivalents were $46.485 million, down from $56.409 million at December 31, 2022. Working capital was approximately $43.4 million; accumulated deficit was $213.6 million. Total liabilities were $7.5 million, principally current liabilities and operating lease obligations; the company reported no outstanding debt or committed credit facility. Gross margin and operating margin are not meaningful because Eledon reported no product revenue.
Material changes versus the prior comparable period
- Net loss increased $0.9 million year over year, while operating expenses increased $1.3 million.
- R&D expense rose $1.5 million, mainly from higher external clinical-trial costs and personnel expense, partly offset by lower stock-based compensation, manufacturing and consulting costs.
- G&A expense declined $0.2 million, primarily due to lower stock-based compensation. Other income improved largely because of higher interest income.
- Operating cash use increased $1.8 million year over year. Cash declined $9.9 million during Q1 2023.
- In January 2023, Eledon prioritized kidney-transplant programs, discontinued its islet-cell transplantation program and deprioritized IgA nephropathy (IgAN).
Outlook, management commentary, risks and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern, given recurring losses, expected future losses and the need for additional financing. The filing says available resources are insufficient to continue ALS clinical development without dedicated additional financing.
- Financing after quarter-end: The company received $35.0 million gross in the initial closing of a private placement on May 5, 2023, after issuing common shares and pre-funded warrants. The agreement provides for potential additional tranche financing of up to $105.0 million, subject to clinical milestones and trading conditions, and up to $45.5 million if all initial common warrants are exercised. These amounts are not assured. The financing creates substantial potential dilution.
- Clinical outlook: Eledon reported March 2023 safety and efficacy results from its kidney-transplant Phase 1b study and planned to begin enrollment in a controlled Phase 2 kidney-transplant study in Q3 2023. The ALS Phase 2a study met its stated safety and tolerability endpoints, but further clinical development depends on obtaining specific additional financing. The company did not plan to initiate the low-dose cohort in its IgAN study.
- Bank exposure: Eledon reported that approximately 78% of its cash was held at Silicon Valley Bank when it failed in March 2023. The company subsequently diversified deposits; as of the report date, less than 5% of total cash was in FDIC-insured banking accounts. The filing notes that cash deposits and investments remain exposed to financial-institution, credit and liquidity risks.
- Other risks and contingencies: Key risks include clinical and regulatory uncertainty, dependence on third-party manufacturers and CROs, future financing needs, possible dilution, competition, and potential trial delays or safety issues. No material legal proceeding or contingent liability requiring accrual was reported. Lease expense was approximately $0.1 million in each comparison quarter.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2023, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the conditional second and third private-placement closings’ milestones and market conditions are achieved, and the resulting cash proceeds and dilution.
- Actual cash burn and financing runway following the May 2023 private-placement proceeds; the filing does not provide a clear cash-runway estimate.
- Timing and enrollment progress for the planned Phase 2 kidney-transplant trial and the availability of funding for further ALS development.
- Updated clinical safety and efficacy evidence, including whether early-stage results are confirmed in later trials.
- Cash and investment concentration, as well as the effects of financing, trial spending and any future capital raises on liquidity and going-concern risk.